Biomet, Inc. Extends Registered Exchange Offers

WARSAW, Ind.--(Business Wire)--
Biomet, Inc. today announced the extension of exchange offers for
all of its outstanding 10% Senior Notes due 2017, 10 3/8%/11 1/8%
Senior Toggle Notes due 2017 and 11 5/8% Senior Subordinated Notes due
2017, which are not registered under the Securities Act of 1933 (the
"Original Notes") for an equal principal amount of its 10% Senior
Notes due 2017, 10 3/8%/11 1/8% Senior Toggle Notes due 2017 and 11
5/8% Senior Subordinated Notes due 2017, respectively, which have been
registered under the Securities Act of 1933 (the "Exchange Notes").

The exchange offers were originally scheduled to expire at 5:00
p.m., New York City time, on Thursday, June 19, 2008. The exchange
offers are now scheduled to expire at 5:00 p.m., New York City time,
on Thursday, June 26, 2008, unless the exchange offers are extended or
terminated by Biomet. As of 5:00 p.m., New York City time, on
Thursday, June 19, 2008, $775,000,000 of the $775,000,000 aggregate
principal amount of the outstanding 10% Senior Notes due 2017,
$774,798,000 of the $775,000,000 aggregate principal amount of the
outstanding 10 3/8%/11 1/8% Senior Toggle Notes due 2017 and
$1,004,067,000 of the $1,015,000,000 aggregate principal amount of the
outstanding 11 5/8% Senior Subordinated Notes due 2017 had been
tendered for exchange.

This press release does not constitute an offer to purchase any
securities or the solicitation of an offer to sell any securities. The
exchange offers are being made only pursuant to the prospectus dated
May 21, 2008 and the related letter of transmittal and only to such
persons and in such jurisdictions as is permitted under applicable
law.

The terms of the exchange offers and other information relating to
Biomet, Inc. are set forth in the prospectus dated May 21, 2008.
Copies of the prospectus and the related letter of transmittal may be
obtained from Wells Fargo Bank, N.A., which is serving as the exchange
agent for the exchange offers. Wells Fargo Bank's address, telephone
and facsimile number are as follows:

-0-
*T
By Registered and Certified Mail:

Wells Fargo Bank, N.A.
Corporate Trust Operations
MAC N9303-121
P.O. Box 1517
Minneapolis, MN 55480

By Overnight Courier or Regular Mail:

Wells Fargo Bank, N.A.
Corporate Trust Operations
MAC N9303-121
6th & Marquette Avenue
Minneapolis, MN 55479

By Hand Delivery:

Wells Fargo Bank, N.A.
Corporate Trust Services
608 2nd Avenue South
Northstar East Building--12th Floor
Minneapolis, MN 55402

By Facsimile Transmission:
(612) 667-6282

Confirm by Telephone:
(800) 344-5128
*T

About Biomet

Biomet, Inc. and its subsidiaries design, manufacture, and market
products used primarily by musculoskeletal medical specialists in both
surgical and non-surgical therapy. Biomet's product portfolio
encompasses reconstructive products, including orthopedic joint
replacement devices, bone cements and accessories, autologous
therapies and dental reconstructive implants; fixation products,
including electrical bone growth stimulators, internal and external
orthopedic fixation devices, craniomaxillofacial implants and bone
substitute materials; spinal products, including spinal stimulation
devices, spinal hardware and orthobiologics; and other products, such
as arthroscopy products and softgoods and bracing products.
Headquartered in Warsaw, Indiana, Biomet and its subsidiaries
currently distribute products in more than 70 countries.

Forward-Looking Statements

This press release contains certain statements that are
"forward-looking statements" within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act
of 1934, as amended. Such statements are qualified by the inherent
risks and uncertainties surrounding future expectations generally,
including those relating to the exchange offers described above, and
may materially differ from actual future experience involving any one
or more of such statements. Such risks and uncertainties include our
ability to develop and market new products and technologies in a
timely manner, and the risk factors as set forth in the registration
statement relating to the exchange offers. The inclusion of a
forward-looking statement herein should not be regarded as a
representation by Biomet that Biomet's objectives will be achieved.
Biomet undertakes no obligation to publicly update forward-looking
statements, whether as a result of new information, future events or
otherwise.

Biomet, Inc.
Daniel P. Florin, 574-372-1687
Senior Vice President and Chief Financial Officer
or
Barbara Goslee, 574-372-1514
Director, Corporate Communications

Copyright Business Wire 2008